Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels.

Provided herein are compounds and methods of use thereof for the modulation of VAP-1 activity.

Provided herein are compounds and methods of use thereof for the modulation of VAP-1 activity.

The present invention relates to novel compounds of general formula (I):

##STR00001##

with A being A1 or A.sup.2:

##STR00002##

and
in which T, X, Y, Ro, R.sup.1, R.sup.10 and R.sup.11 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.

The present invention relates to novel compounds of general formula (I):

##STR00001##

with A being A1 or A.sup.2:

##STR00002##

and
in which T, X, Y, Ro, R.sup.1, R.sup.10 and R.sup.11 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.

Provided is an additive for imparting ultraviolet absorbency, or an additive for imparting a high refractive index, which has satisfactory compatibility with a resin serving as a matrix and can maintain high transparency even if added in high concentrations. Also provided is an additive with which the function of imparting both ultraviolet absorbency and a high refractive index can be realized by means of one kind of additive. This additive is represented by the following Formula (I): ##STR00001## wherein at least one of R.sup.1a to R.sup.9a is a monovalent sulfur-containing group represented by the following Formula (i-1) or Formula (i-2):
R.sup.10a.sub.mSH  (i-1)
R.sup.11a.sub.nSR.sup.12a—S.sub.pR.sup.13a  (i-2) wherein R.sup.10a to R.sup.12a each represent a divalent hydrocarbon group or the like; and R.sup.13a represents a monovalent hydrocarbon group or the like.

The present invention belongs to the technical field of petrochemical engineering, and relates to a method for continuous post-treatment of benzotriazole (abbreviated as BTA) synthetic fluid. In particular, the present invention relates to a method for synthesizing BTA, including subjecting the BTA synthetic fluid to post-treatment steps of continuous acidification, water washing, extraction, back-extraction, dehydration, and distillation and the like. The method utilizes the difference in solubility of the BTA in water under different pHs to achieve separation by extraction without consuming a large amount of evaporation energy. The present invention is easy to operate, has little environmental pollution, high economic efficiency and low energy consumption, and is easily industrialized.

The present invention belongs to the technical field of petrochemical engineering, and relates to a method for continuous post-treatment of benzotriazole (abbreviated as BTA) synthetic fluid. In particular, the present invention relates to a method for synthesizing BTA, including subjecting the BTA synthetic fluid to post-treatment steps of continuous acidification, water washing, extraction, back-extraction, dehydration, and distillation and the like. The method utilizes the difference in solubility of the BTA in water under different pHs to achieve separation by extraction without consuming a large amount of evaporation energy. The present invention is easy to operate, has little environmental pollution, high economic efficiency and low energy consumption, and is easily industrialized.

Disclosed herein are novel compounds that inhibit fructokinase (KHK or ketohexokinase) and the downstream metabolic effects mediated by fructose metabolism. Fructokinase inhibitors specifically block the metabolism of both dietary and endogenous fructose metabolism and have a host of potential metabolic benefits.

Disclosed herein are novel compounds that inhibit fructokinase (KHK or ketohexokinase) and the downstream metabolic effects mediated by fructose metabolism. Fructokinase inhibitors specifically block the metabolism of both dietary and endogenous fructose metabolism and have a host of potential metabolic benefits.